Stryker’s Q Guidance System Scores FDA Clearance For Cranial Applications
Stryker Corporation (NYSE:SYK) announced that its Q Guidance System with Cranial Guidance Software received FDA510(k) clearance. The Q Guidance System…
ReShape Lifesciences Has Received A Notice Of Allowance For Its U.S. Patent Application 16/326,607 Titled “Gastric Vest For Restriction Of The Stomach To Treat Obesity”
https://patentcenter.uspto.gov/#!/applications/16326607/ifw/docs
Bristol Myers Squibb Announces Adjuvant Opdivo Continues To Provide Significant, Durable Clinical Benefits For Patients With Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years In CheckMate -274 Trial
Three-year median follow-up data demonstrate significantly improved disease-free survival, non-urothelial tract recurrence-free survival, distant metastasis-free survival and second progression-free survival with
‘Maker Of Promising Alzheimer’s Drug Leqembi Expects Full FDA Approval This Summer, Expanded Medicare Coverage’ – CNBC
https://www.cnbc.com/2023/02/17/maker-of-promising-alzheimer-drug-leqembi-expects-fdas-full-approval-this-summer.html
Eisai is anticipating full FDA approval of its early Alzheimer’s treatment, Leqembi, as soon
Trodelvy Demonstrates Efficacy Treating Both Platinum-Ineligible And Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
– Oral Presentation Highlights Trodelvy Efficacy of 13.5 Months Overall Survival in Patients with Platinum-Ineligible Metastatic UC After Checkpoint Inhibitor Therapy –
– Trodelvy Demonstrated
Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent Asserted Against Hologic; The U.S. Court Of Appeals Rejected Minerva’s Arguments On Appeal And As A Result, Minerva Had To Pay Hologic More Than $7.4M
Hologic, Inc. (NASDAQ:HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit unanimously affirmed a 2021 district court ruling that invalidated a Minerva patent asserted against Hologic. The
Pfizer, Valneva Discontinue Certain Trial Sites For Phase 3 Study Of Lyme Disease Vaccine Candidate
Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announce that Pfizer, as the study sponsor, will discontinue a significant percentage of participants in the…
Pfizer Releases Interim Update On PARP Inhibitor Combo Therapy For Prostate Cancer, Secures FDA Priority Review
Pfizer Inc (NYSE:PFE) announced results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) in 1,106…
Merck’s KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone In Patients With HER2-Negative Gastric Or Gastroesophageal Junction Adenocarcinoma Regardless Of PD-L1 Expression
In KEYNOTE-859, KEYTRUDA combined with chemotherapy also showed statistically significant improvements in progression-free survival and objective response rate, the trial's key secondary endpoints, compared with
First AML Patient Transplanted With Vor Bio’s Trem-Cel Demonstrated Durable Engraftment through Multiple Mylotarg Cycles At Initial Dose Level
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg
Mylotarg treatment enriched CD33-negative donor hematopoiesis
Second patient successfully received trem-cel